Merck: priority review for Lynparza
(CercleFinance.com) - AstraZeneca and Merck & Co announce that an application for approval of Lynparza (olaparib), in combination with bevacizumab, has been accepted for priority review in the United States, for first-line maintenance treatment in advanced ovarian cancer.
This FDA priority review was granted based on the results of the pivotal phase III PAOLA-1 trial, which were published in The New England Journal of Medicine, a trial comparing the Lynparza-bevacizumab combination with bevacizumab alone.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This FDA priority review was granted based on the results of the pivotal phase III PAOLA-1 trial, which were published in The New England Journal of Medicine, a trial comparing the Lynparza-bevacizumab combination with bevacizumab alone.
Copyright (c) 2020 CercleFinance.com. All rights reserved.